喉副神经节瘤1例

doi:10.11798/j.issn.1007-1520.202322397

首页 > 按月查看>2023年第6期 >97-101. DOI:10.11798/j.issn.1007-1520.202322397

喉副神经节瘤1例
DOI:
                        10.11798/j.issn.1007-1520.202322397
                    
作者:
                        程小凌程小凌
兰州大学第一临床医学院, 甘肃 兰州 730000
在知网中查找
在百度中查找
在本站中查找
卫旭东卫旭东
兰州大学第一临床医学院, 甘肃 兰州 730000;甘肃省人民医院 耳鼻咽喉头颈外科, 甘肃 兰州 730000
在知网中查找
在百度中查找
在本站中查找
周威邦周威邦
兰州大学第一临床医学院, 甘肃 兰州 730000
在知网中查找
在百度中查找
在本站中查找
李雪雪李雪雪
兰州大学第一临床医学院, 甘肃 兰州 730000
在知网中查找
在百度中查找
在本站中查找

                    
作者单位:
作者简介:
通讯作者:
基金项目:甘肃省人民医院院内科研基金项目(20GSSY6-2)；甘肃省自然科学基金项目(20JR10RA377)。

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

摘要:

网友评论

分享到微博

发布

参考文献

[1] Lenders JWM, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma[J].Lancet, 2005, 366(9486):665-675.

[2] Dahia PL. Pheochromocytoma and paraganglioma pathogenesis:learning from genetic heterogeneity[J]. Nat Rev Cancer, 2014, 14(2):108-119.

[3] Levy MT, Braun JT, Pennant M, et al. Primary paraganglioma of the parathyroid:a case report and clinicopathologic review[J]. Head Neck Pathol, 2010, 4(1):37-43.

[4] Myssiorek D, Ferlito A, Silver CE, et al. Screening for familial paragangliomas[J]. Oral Oncol, 2008, 44(6):532-537.

[5] Castro-Vega LJ, Lepoutre-Lussey C, Gimenez-Roqueplo AP, et al. Rethinking pheochromocytomas and paragangliomas from a genomic perspective[J]. Oncogene, 2016, 35(9):1080-1089.

[6] Offergeld C, Brase C, Yaremchuk S, et al. Head and neck paragangliomas:clinical and molecular genetic classification[J]. Clinics (Sao Paulo), 2012, 67 Suppl 1(Suppl 1):19-28.

[7] Szymańska A, Szymański M, Czekajska-Chehab E, et al. Diagnosis and management of multiple paragangliomas of the head and neck[J]. Eur Arch Otorhinolaryngol, 2015, 272(8):1991-1999.

[8] 焦新芳, 龚巍, 陈琳瑶, 等. 头颈部多发副神经节瘤的诊疗分析和文献复习[J]. 中国耳鼻咽喉颅底外科杂志, 2017, 23(6):529-535.

[9] Merzouqi B, El Bouhmadi K, Oukesou Y, et al. Head and neck paragangliomas:Ten years of experience in a third health center. A cohort study[J]. Ann Med Surg (Lond), 2021, 66:102412.

[10] Papagiannopoulos P, Raman A, Miller C, et al. Laryngeal paraganglioma with chronic cough:a case report[J]. Turk Arch Otorhinolaryngol, 2018, 56(4):233-236.

[11] Fliedner SM, Lehnert H, Pacak K. Metastatic paraganglioma[J]. Semin Oncol, 2010, 37(6):627-637.

[12] Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma:a population level analysis of long-term survival over two decades[J]. J Surg Oncol, 2013, 107(6):659-664.

[13] Javidiparsijani S, Brickman A, Lin DM, et al. Is regional lymph node metastasis of head and neck paraganglioma a sign of aggressive clinical behavior:a clinical/pathologic review[J]. Ear Nose Throat J, 2021, 100(6):447-453.

[14] Williams MD. Paragangliomas of the head and neck:an overview from diagnosis to genetics[J]. Head Neck Pathol, 2017, 11(3):278-287.

[15] Pillai S, Gopalan V, Smith RA, et al. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era[J]. Crit Rev Oncol Hematol, 2016, 100:190-208.

[16] Opocher G, Schiavi F. Genetics of pheochromocytomas and paragangliomas[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(6):943-956.

[17] Crona J, Taïeb D, Pacak K. New Perspectives on pheochromocytoma and paraganglioma:toward a molecular classification[J]. Endocr Rev, 2017, 38(6):489-515.

[18] Guha A, Chovanec M. Head and neck paragangliomas in the Czech Republic:Management at the otorhinolaryngology department[J]. Diagnostics (Basel), 2021, 12(1):28.

[19] Khatami F, Mohammadamoli M, Tavangar SM. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs)[J]. Endocr Regul, 2018, 52(1):41-54.

[20] Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma[J]. Cancer Cell, 2017, 31(2):181-193.

[21] Dahia PL. Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once![J]. Cancer Cell, 2017, 31(2):159-161.

[22] Kavinga Gunawardane PT, Grossman A. The clinical genetics of phaeochromocytoma and paraganglioma[J]. Arch Endocrinol Metab, 2017, 61(5):490-500.

[23] Gupta N, Strome SE, Hatten KM. Is routine genetic testing warranted in head and neck paragangliomas?[J]. Laryngoscope, 2019, 129(7):1491-1493.

[24] Majewska A, Budny B, Ziemnicka K, et al. Head and Neck Paragangliomas-A Genetic Overview[J]. Int J Mol Sci, 2020, 21(20):7669.

[25] Pavlov VS, Kalinin DV, Lukyanova EN, et al. Multiple paragangliomas:a case report[J]. BMC Med Genomics, 2020, 13(Suppl 8):125.

[26] Koopman K, Gaal J, de Krijger RR. Pheochromocytomas and paragangliomas:new developments with regard to classification, genetics, and cell of origin[J]. Cancers (Basel), 2019, 11(8):1070.

[27] Ding Y, Li L, Han D, et al. Head and neck malignant paragangliomas:Experience from a single institution[J]. Ear Nose Throat J, 2021:1455613211052338.

[28] Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma[J]. J Clin Endocrinol Metab, 2009, 94(12):4757-4767.

[29] 中华医学会内分泌学分会肾上腺学组. 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J]. 中华内分泌代谢杂志, 2016, 32(3):181-187.

[30] van Berkel A, Vriens D, Visser EP, et al. Metabolic subtyping of pheochromocytoma and paraganglioma by (18)F-FDG pharmacokinetics using dynamic PET/CT scanning[J]. J Nucl Med, 2019, 60(6):745-751.

[31] Cleere EF, Martin-Grace J, Gendre A, et al. Contemporary management of paragangliomas of the head and neck[J]. Laryngoscope Investig Otolaryngol, 2022, 7(1):93-107.

[32] Koopmans KP, Jager PL, Kema IP, et al. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas[J]. J Nucl Med, 2008, 49(8):1232-1237.

[33] Janssen I, Chen CC, Millo CM, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma[J]. Eur J Nucl Med Mol Imaging, 2016, 43(10):1784-1791.

[34] Janssen I, Chen CC, Zhuang Z, et al. Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes[J]. J Nucl Med, 2017, 58(8):1236-1242.

[35] Thelen J, Bhatt AA. Multimodality imaging of paragangliomas of the head and neck[J]. Insights Imaging, 2019, 10(1):29.

[36] Abt NB, Holcomb AJ, Shroff S, et al. Intralaryngeal paraganglioma workup and discussion of surgical approach[J]. BMJ Case Rep, 2020, 13(6):e234745.

[37] Fishbein L. Pheochromocytoma and paraganglioma:genetics, diagnosis, and treatment[J]. Hematol Oncol Clin North Am, 2016, 30(1):135-150.

[38] Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine:recommendation from a 22-year follow-up of 18 patients[J]. Cancer, 2008, 113(8):2020-2028.

[39] Jimenez P, Tatsui C, Jessop A, et al. Treatment for Malignant Pheochromocytomas and Paragangliomas:5 Years of Progress[J]. Curr Oncol Rep, 2017, 19(12):83.

[40] Lloyd S, Obholzer R, Tysome J. British skull base society clinical consensus document on management of head and neck paragangliomas[J]. Otolaryngol Head Neck Surg, 2020, 163(3):400-409.

引用本文

程小凌,卫旭东,周威邦,李雪雪.喉副神经节瘤1例[J].中国耳鼻咽喉颅底外科杂志,2023,29(6):97-101

复制

文章指标

点击次数:68
下载次数: 172

历史

收稿日期:2022-09-30
最后修改日期:
录用日期:
在线发布日期: 2024-01-04

期刊首页

期刊简介

编委会

版权协议

期刊浏览

期刊订阅

广告合作

联系我们

引用本文

分享

文章指标

历史